



Express Mail No.: D R A F T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sommadossi, *et al.*

Confirmation No.: 8101

Serial No.: 10/607,909

Art Unit: 1623

Filed: June 27, 2003

Examiner: Travis C. McIntosh III

For: 2'-C-METHYL-3'-O-L-VALINE
ESTER RIBOFURANOSYL
CYTIDINE FOR TREATMENT
OF FLAVIVIRIDAE
INFECTIONS

Attorney Docket No.: 11874-026-999
(417451-999026)
IDX 1031

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner ADOLFO LAI represents that he holds the position of
PRORETTORE of Università Degli Studi Di Cagliari, the
assignee of less than the entire right, title and interest in and to the above identified application
by virtue of an assignment which was recorded on October 19, 2006 at reel 018411 frame 0957.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified
application which would extend beyond the expiration date of the patent granted on U.S. Patent
Application No. 10/609,298, filed June 27, 2003 and hereby agrees that any patent so granted on
the above identified application shall be enforceable only for and during such period that the
legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent
Application No. 10/609,298.

Petitioner further agrees that this agreement is to run with any patent granted on the
above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-
identified application prior to the expiration date of the full statutory term of the patent granted
on U.S. Patent Application No. 10/609,298 in the event that said patent later expires for failure to
pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole



Express Mail No.: D R A F T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sommadossi, <i>et al.</i>	Confirmation No.:	8101
Serial No.:	10/607,909	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	Travis C. McIntosh III
For:	2'-C-METHYL-3'-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS	Attorney Docket No.:	11874-026-999 (417451-999026) IDX 1031

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner Jean-Pierre Sommadossi represents that he holds the position of President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., the assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment which was recorded on October 19, 2006 at reel 018411 frame 0831.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of the patent granted on U.S. Patent Application No. 10/609,298, filed June 27, 2003 and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent Application No. 10/609,298.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of the patent granted on U.S. Patent Application No. 10/609,298 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole

or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Idenix Pharmaceuticals, Inc.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 10th day of September 2007.

Idenix Pharmaceuticals, Inc.

By: _____

Name: Jean-Pierre Sommadossi

Position: President and Chief Executive Officer



Express Mail No.: D R A F T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sommadossi, <i>et al.</i>	Confirmation No.:	8101
Serial No.:	10/607,909	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	Travis C. McIntosh III
For:	2'-C-METHYL-3'-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS	Attorney Docket No.:	11874-026-999 (417451-999026)
		CNRS ref.:	85256-09
		Idenix ref.:	IDX 1031

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner Frederic Foubert represents that he holds the position of Directeur du Service du Transfert de Technologies of Centre National De La Recherche Scientifique, the assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment which was recorded on March 22, 2007 at reel 019052 frame 0892.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of the patent granted on U.S. Patent Application No. 10/609,298, filed June 27, 2003 and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent Application No. 10/609,298.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of the patent granted on U.S. Patent Application No. 10/609,298 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole

or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Centre National De La Recherche Scientifique.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this _____ day of _____, 2007.

Centre National De La Recherche Scientifique

By: _____

Name: Frederic Foubert
Position: Directeur du Service du Transfert de Technologies

10 SEP. 2007

Directeur du Service du Transfert de Technologies

Frédéric FOUBERT



Directeur de la Politique Industrielle

Marc J. LEDOUX